Yerly-Motta V, Contassot E, Pavy J J, Tiberghien P, Hervé P
Cellular Immunology and Immunomolecular Therapeutic Laboratories, ETS Franche-Comté, Besançon, France.
Cell Mol Biol (Noisy-le-grand). 1999 Dec;45(8):1217-28.
The overexpression and/or amplification of cell cycle regulating genes is an important factor in the progression of cancer. Recent attention has been focused on several cyclin and cdks genes whose expression were increased in many types of tumor. In this study, we investigated the expression kinetics of cyclins A, B, D1, E and cdks 1, 2, 4, 6 by RT-PCR coupled with densitometry and correlated to the growth fraction (percentage of S cells). This analysis was performed using an experimental murine leukemic model, generated by in vivo administration of murine clonogenic cells Wehi-3b injected into balb-c mice. Differential expression of cyclins and cdks was observed between normal and tumoral cells with different patterns of expression between G1 and G2M cyclins-cdks. G1 cyclins cdks expression was significantly increased in tumor cells when compared to normal cells. In the same manner, G2M cyclins cdks expression was only observed in tumor cells at a lower level than for G1 cyclins cdks, but not detected in normal cells. These differences correlated with the growth fraction for both the G1 cyclins cdks (r = 0.91, 0.94, 0.85, 0.90 and 0.96 for cyclin D1, cyclin E, cdk2, cdk4 and cdk6, respectively) and the G2M cyclins cdks (r = 0.96, 0.97 and 0.93 for cyclins A, B and cdkl respectively). Analysis of cyclins cdks expression kinetics during tumoral progression shows that cyclins A, B and cdkl were expressed from the 12th day on of disease, increased until the death of the animals and correlated with the growth fraction (r = 0.94, 0.95 and 0.97 for cyclins A, B and cdk1 respectively) (n = 20). Overexpression of other cyclins cdks were observed, from the 6th day on for cyclin D1, the 12th day for cdk2 and cdk4, the 15th day for cdk6 and the 20th day for cyclin E. These increases persisted during tumoral progression and correlated with the growth fraction (r = 0.85, 0.94, 0.93, 0.96, and 0.98 for cyclin D1, cyclin E, cdk2, cdk4 and cdk6, respectively) (n = 20). Our results demonstrated that G1 and G2-M cyclins cdks mRNA levels were increased at approximately the same time of maximal tumor growth. Only cyclin D1 overexpression occured at the initiation of tumoral development, and could therefore be considered as an early marker of cell proliferation.
细胞周期调控基因的过表达和/或扩增是癌症进展的一个重要因素。最近,人们的注意力集中在几种细胞周期蛋白和周期蛋白依赖性激酶(cdk)基因上,它们在多种肿瘤中的表达均有所增加。在本研究中,我们通过逆转录聚合酶链反应(RT-PCR)结合光密度测定法,研究了细胞周期蛋白A、B、D1、E和周期蛋白依赖性激酶1、2、4、6的表达动力学,并将其与生长分数(S期细胞百分比)相关联。该分析使用了一种实验性小鼠白血病模型,该模型通过向BALB-c小鼠体内注射小鼠克隆形成细胞Wehi-3b生成。在正常细胞和肿瘤细胞之间观察到细胞周期蛋白和周期蛋白依赖性激酶的差异表达,G1期和G2/M期细胞周期蛋白-周期蛋白依赖性激酶之间具有不同的表达模式。与正常细胞相比,肿瘤细胞中G1期细胞周期蛋白-周期蛋白依赖性激酶的表达显著增加。同样,G2/M期细胞周期蛋白-周期蛋白依赖性激酶的表达仅在肿瘤细胞中观察到,其水平低于G1期细胞周期蛋白-周期蛋白依赖性激酶,但在正常细胞中未检测到。这些差异与G1期细胞周期蛋白-周期蛋白依赖性激酶(细胞周期蛋白D1、细胞周期蛋白E、周期蛋白依赖性激酶2、周期蛋白依赖性激酶4和周期蛋白依赖性激酶6的r值分别为0.91、0.94、0.85、0.90和0.96)以及G2/M期细胞周期蛋白-周期蛋白依赖性激酶(细胞周期蛋白A、细胞周期蛋白B和周期蛋白依赖性激酶1的r值分别为0.96、0.97和0.93)的生长分数相关。对肿瘤进展过程中细胞周期蛋白-周期蛋白依赖性激酶表达动力学的分析表明,细胞周期蛋白A、B和周期蛋白依赖性激酶1从疾病第12天开始表达,持续增加直至动物死亡,并与生长分数相关(细胞周期蛋白A、细胞周期蛋白B和周期蛋白依赖性激酶1的r值分别为0.94、0.95和0.97)(n = 20)。观察到其他细胞周期蛋白-周期蛋白依赖性激酶的过表达,细胞周期蛋白D1从第6天开始,周期蛋白依赖性激酶2和周期蛋白依赖性激酶4从第12天开始,周期蛋白依赖性激酶6从第15天开始,细胞周期蛋白E从第20天开始。这些增加在肿瘤进展过程中持续存在,并与生长分数相关(细胞周期蛋白D1、细胞周期蛋白E、周期蛋白依赖性激酶2、周期蛋白依赖性激酶4和周期蛋白依赖性激酶6的r值分别为0.85、0.94、0.93、0.96和0.98)(n = 20)。我们的结果表明,G1期和G2-M期细胞周期蛋白-周期蛋白依赖性激酶的mRNA水平在肿瘤生长最大时大约同时增加。只有细胞周期蛋白D1的过表达发生在肿瘤发展初期,因此可被视为细胞增殖的早期标志物。